Halozyme Therapeutics (HALO) 高级副总裁 Michael J. Labarre 出售 10,000 股股票

Halozyme Therapeutics, Inc.（纳斯达克股票代码：HALO – 获取免费报告）高级副总裁 Michael J. Labarre 在 7 月 24 日星期三的一次交易中出售了 10,000 股该公司股票。

Halozyme Therapeutics, Inc. (NASDAQ:HALO) SVP Michael J. Labarre sold 10,000 shares of the stock in a transaction on Wednesday, July 24th. The shares were sold at an average price of $55.12, for a total value of $551,200.00. Following the completion of the transaction, the senior vice president now directly owns 168,176 shares in the company, valued at approximately $9,269,861.12. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Halozyme Therapeutics, Inc.（纳斯达克股票代码：HALO）高级副总裁 Michael J. Labarre 在 7 月 24 日星期三的一次交易中出售了 10,000 股该公司股票。这些股票的平均售价为 55.12 美元，总价值为 551,200.00 美元。交易完成后，高级副总裁现直接拥有公司168,176股，价值约9,269,861.12美元。该交易已在向美国证券交易委员会提交的文件中披露，可通过此超链接访问该文件。

Halozyme Therapeutics Stock Performance

Halozyme Therapeutics 股票表现

Shares of HALO opened at $55.15 on Thursday. The company has a 50-day simple moving average of $49.62 and a two-hundred day simple moving average of $42.35. Halozyme Therapeutics, Inc. has a one year low of $32.83 and a one year high of $56.50. The firm has a market capitalization of $7.02 billion, a PE ratio of 22.79, a price-to-earnings-growth ratio of 0.56 and a beta of 1.27. The company has a debt-to-equity ratio of 8.44, a current ratio of 6.64 and a quick ratio of 5.36.

HALO 股价周四开盘价为 55.15 美元。该公司的 50 天简单移动平均线为 49.62 美元，200 天简单移动平均线为 42.35 美元。 Halozyme Therapeutics, Inc. 的一年最低价为 32.83 美元，一年最高价为 56.50 美元。该公司市值为70.2亿美元，市盈率为22.79，市盈增长率为0.56，贝塔值为1.27。该公司的债务股本比率为8.44，流动比率为6.64，速动比率为5.36。

Halozyme Therapeutics (NASDAQ:HALO) last released its earnings results on Tuesday, May 7th. The biopharmaceutical company reported $0.71 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.64 by $0.07. Halozyme Therapeutics had a net margin of 36.94% and a return on equity of 225.71%. The firm had revenue of $195.88 million during the quarter, compared to analyst estimates of $201.72 million. On average, analysts anticipate that Halozyme Therapeutics, Inc. will post 3.66 EPS for the current fiscal year.

Halozyme Therapeutics（纳斯达克股票代码：HALO）最近于 5 月 7 日星期二发布了财报。该生物制药公司报告本季度每股收益 (EPS) 为 0.71 美元，比市场普遍预期的 0.64 美元高出 0.07 美元。 Halozyme Therapeutics 的净利润率为 36.94%，股本回报率为 225.71%。该公司本季度营收为 1.9588 亿美元，而分析师预计为 2.0172 亿美元。分析师平均预计 Halozyme Therapeutics, Inc. 本财年的每股收益将为 3.66。

Wall Street Analysts Forecast Growth

华尔街分析师预测增长

Read Our Latest Report on Halozyme Therapeutics

阅读我们关于 Halozyme 疗法的最新报告